期刊文献+

反义寡核苷酸对Daudi细胞α2,6唾液酸的下调作用研究

A Study of Antisense-Oligonucleotides in Down-Regulation of α2,6-Sialylation of Daudi Cells
下载PDF
导出
摘要 目的 研究反义寡核苷酸对Burkitt’s淋巴瘤Daudi细胞α2 ,6 唾液酸转移酶 (ST6GalI)的活性和细胞表面α2 ,6 唾液酸水平的下调作用。方法 以修饰后的ST6GalI的反义寡核苷酸处理Daudi细胞 ,以RT PCR检测Daudi细胞ST6GalImRNA的表达 ,荧光定量法测定ST6GalI的活性及以流式细胞仪检测细胞表面α2 ,6 唾液酸的含量。结果 和对照组比较 ,以反义寡核苷酸处理的Daudi细胞ST6GalImRNA的表达下调 ,ST6GalI酶活性下降 ,并导致细胞表面α2 ,6 唾液酸水平降低。结论 反义寡核苷酸可有效降低Daudi细胞表面α2 ,6 唾液酸化水平 ,内源性减少α2 ,6 唾液酸对Daudi细胞CD2 Objective To study the antisense oligonucleotides (antisense ODN) in down regulation of α2,6 sialyltransferase (ST6Gal I) activity and α2,6 sialylation of cell surface of Burkitt's lymphoma cell line Daudi.Methods Daudi cells were treated with modified antisense ODN in vitro, the ST6Gal I mRNA expression was examined by RT PCR, the ST6Gal I enzyme activity was measured with fluorometric sialyltransferase assay and the amount of α2,6 sialylation of cell surface was determined by FACS analysis.Results Antisense ODN treatment led to a down regulation of ST6Gal I mRNA expression and enzyme activity of Daudi cells and resulted in a reduced α2,6 sialylation of cell surface compared with the control group.Conclusion Antisense ODN is of relevance in decreasing the α2,6 sialylation of Daudi cell surface and may endogenously reduce the masking of CD22 by the α2,6 sialylation.
出处 《肿瘤防治研究》 CAS CSCD 2004年第6期338-340,共3页 Cancer Research on Prevention and Treatment
基金 国家 973项目子课题(2 0 0 1CB5 10 2 0 8)基金资助项目
关键词 反义寡核苷酸 唾液酸转移酶 Burkitt's 淋巴瘤 CD22 Antisense-oligonucleotides Sialyltransferase Burkitts lymphoma CD22
  • 相关文献

参考文献14

  • 1[1]Tedder TF, Tuscano J, Sato S, et al. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signalling[J]. Annu Rev Immunol, 1997, 15(): 481-504.
  • 2[2]Siegel AB, Goldenberg DM, Cesano A, et al. CD22-Directed Monoclonal Antibody Therapy for Lymphoma[J]. Semi Oncol, 2003, 30 (4):457-464.
  • 3[3]Cesano A, Gayko U. CD22 as a Target of Passive Immunotherapy[J]. Semi Oncol, 2003, 30(2):253-257.
  • 4[4]Razi N, Varki A. Masking and unmasking of CD22 lectin function in resting and activated B-lymphocytes[J]. Proc Natl Acad Sci USA, 1998, 95(13): 7469-7474.
  • 5[5]Danzer CP, Colllins BE, Blixt O, et al. Transitional and marginal zone B cells have a high proportion of unmasked CD22: implications for BCR signaling[J]. Int Immunol, 2003, 15(10): 1137-1147.
  • 6[6]Lin S,Kemmner W,Grigull S,et al. Cell surface α2,6-Sialylation affects adhesion of breast carcinoma cells[J]. Exp Cell Res, 2002, 276(1): 101-110.
  • 7[7]Wuensch SA, Huang RY, Ewing J, et al. Murine B cell differentiation is accompanied by programmed expression of multiple novel beta-galactoside alpha2, 6-sialyltransferase mRNA forms[J].Glycobiology, 2000, 10(1): 67-75.
  • 8[8]Hennet T, Chui D, Paulson JC, et al. Immune regulation by the ST6Gal sialyltransferase[J]. Proc Natl Acad Sci USA, 1998, 95(8): 4504-4509.
  • 9[9]Floyd H, Nitschke L, Crocker PR. A novel subset of murine B cells that expresses unmasked forms of CD22 is enriched in the bone marrow: implications for B-cell homing to the bone marrow[J]. Immunol, 2000, 101(3): 342-347.
  • 10[10]Kelm S, Gerlach J, Brossmer R, et al. The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound[J]. J Exp Med, 2002, 195(9):1207-1213.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部